MEDICAL ONCOLOGY

Scope & Guideline

Delivering impactful knowledge to enhance cancer outcomes.

Introduction

Immerse yourself in the scholarly insights of MEDICAL ONCOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1357-0560
PublisherHUMANA PRESS INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1994 to 2024
AbbreviationMED ONCOL / Med. Oncol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512

Aims and Scopes

The journal "Medical Oncology" is dedicated to advancing the field of cancer treatment and research through the publication of high-quality studies. It encompasses a wide range of topics related to oncology, integrating clinical practice, translational research, and the latest therapeutic advancements.
  1. Clinical Oncology:
    Focuses on the diagnosis, treatment, and management of various cancers, including innovative approaches such as immunotherapy, targeted therapy, and chemotherapy.
  2. Translational Research:
    Bridges laboratory research and clinical applications, emphasizing studies that explore the molecular and genetic aspects of cancer to improve patient outcomes.
  3. Epidemiology and Public Health:
    Investigates the patterns, causes, and effects of cancer in populations, aiming to inform public health strategies and improve cancer prevention and control.
  4. Biomarkers and Prognostic Indicators:
    Explores the identification and validation of biomarkers that aid in cancer diagnosis, prognosis, and treatment response, enhancing personalized medicine.
  5. Emerging Technologies in Oncology:
    Covers advancements in artificial intelligence, machine learning, and other technological innovations that improve cancer diagnostics, treatment planning, and patient care.
The journal has observed a significant evolution in its focus, with several emerging themes that highlight the dynamic landscape of oncology research. These trends reflect advancements in technology, a deeper understanding of cancer biology, and the integration of interdisciplinary approaches.
  1. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning in oncology is gaining traction, with studies exploring their applications in diagnostics, treatment prediction, and personalized medicine.
  2. Immunotherapy and Combination Therapies:
    Research on immunotherapy, particularly in combination with other treatments, is increasingly prominent as it represents a significant advancement in cancer treatment strategies.
  3. Genomics and Precision Medicine:
    The focus on genomics, including the use of genetic profiling to tailor treatments to individual patients, is emerging as a critical area of research in oncology.
  4. Patient-Centered Care and Quality of Life:
    There is a growing emphasis on research that addresses patient-centered outcomes, including quality of life and psychosocial aspects of cancer treatment.
  5. Microbiome and Cancer Interactions:
    Studies investigating the relationship between the microbiome and cancer development or treatment responses are on the rise, indicating a new frontier in oncology research.

Declining or Waning

While the journal continues to thrive in various domains, certain themes are gradually becoming less prominent. This decline may reflect shifting research priorities or advancements in other areas of oncology.
  1. Traditional Chemotherapy Protocols:
    Research focusing solely on conventional chemotherapy protocols is diminishing as novel therapeutic strategies, such as immunotherapy and targeted treatments, gain prominence.
  2. Basic Science Without Clinical Relevance:
    Studies that lack a direct connection to clinical applications or patient outcomes are less frequently published, as there is a growing emphasis on translational research.
  3. Single-Agent Drug Studies:
    Publications concentrating solely on the efficacy of single-agent therapies are decreasing, as combination therapies and personalized medicine approaches take precedence.
  4. Descriptive Epidemiological Studies:
    While epidemiological research remains important, there is a noted decline in descriptive studies that do not offer intervention insights or actionable recommendations.
  5. Outdated Diagnostic Techniques:
    Research centered around outdated diagnostic methods is waning as newer, more accurate technologies and approaches are developed and adopted.

Similar Journals

Expert Review of Anticancer Therapy

Navigating the complexities of oncology with expert guidance.
Publisher: TAYLOR & FRANCIS LTDISSN: 1473-7140Frequency: 12 issues/year

Expert Review of Anticancer Therapy, published by Taylor & Francis Ltd, is a distinguished journal focusing on the dynamic and ever-evolving field of oncology and pharmacology. Since its inception in 2001, this journal has played a pivotal role in disseminating critical reviews and analyses of novel anticancer therapies, fostering a deeper understanding among researchers and practitioners alike. With an impressive categorization in the 2023 Q2 quartiles for both Oncology and Pharmacology, it ranks #98 out of 272 in Pharmacology and #165 out of 404 in Oncology according to Scopus metrics, placing it well within the upper echelons of academic journals. The journal’s rigorous peer-review process ensures high-quality publications that are integral for advancing cancer research and therapeutic strategies. Although currently not an open access journal, it aims to bridge the gap between scientific discovery and clinical application, making it an essential resource for anyone involved in the fight against cancer.

ANNALS OF ONCOLOGY

Exploring the complexities of cancer treatment and care.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

PATHOLOGY & ONCOLOGY RESEARCH

Transforming Understanding in Pathology and Oncology
Publisher: FRONTIERS MEDIA SAISSN: 1219-4956Frequency: 1 issue/year

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Journal of Gastrointestinal Oncology

Connecting experts to tackle gastrointestinal oncology challenges.
Publisher: AME PUBLISHING COMPANYISSN: 2078-6891Frequency: 6 issues/year

The Journal of Gastrointestinal Oncology, published by AME Publishing Company, is a leading open-access journal that focuses on the complex interplay between gastroenterology and oncology. Established in 2012 and converging into a reputable academic platform through 2024, the journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and management of gastrointestinal cancers. With an ISSN of 2078-6891 and an E-ISSN of 2219-679X, this journal presents articles that are rigorously peer-reviewed, ensuring high-quality content that meets the demands of the scientific community. Despite its current categorization in the Q3 quartile for both Gastroenterology and Oncology as of 2023, it consistently strives to improve its impact and relevance, reflected in its Scopus rankings and percentile metrics. Publishing noteworthy research, reviews, and case studies, the Journal of Gastrointestinal Oncology is instrumental in addressing significant challenges in the field, making it a must-read for those dedicated to advancing knowledge and practice in gastrointestinal oncology.

CLINICAL ONCOLOGY

Empowering Oncology Professionals with Cutting-Edge Insights
Publisher: ELSEVIER SCIENCE LONDONISSN: 0936-6555Frequency: 6 issues/year

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

Translational Oncology

Transforming Cancer Insights into Clinical Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

CANCER TREATMENT REVIEWS

Uncovering breakthroughs in cancer therapies since 1974.
Publisher: ELSEVIER SCI LTDISSN: 0305-7372Frequency: 10 issues/year

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

ONCOLOGY

Elevating the standards of oncology research and practice.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pioneering Insights in Cancer Treatment and Research.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Shaping the Future of Cancer Care
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.